GlassScriptPhysician profile
Premjit Chahal
NPI 1093893091
$6,319.07
in general payments reported to CMS, 2019-2025
26 companies · $872 in 2025
The $872 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,347 · 2020: $614 · 2021: $420 · 2022: $860 · 2023: $1,089 · 2024: $1,117 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,912.48 | 2020-2025 | Linzess, Viberzi, Creon |
| Braintree Laboratories, INC. | $787.08 | 2019-2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $625.16 | 2020-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $615.51 | 2019-2020 | |
| Pfizer INC. | $565.68 | 2019-2025 | |
| Celgene Corporation | $321.42 | 2022-2023 | Zeposia |
| Medtronic USA, INC. | $159.52 | 2019 | |
| Ferring Pharmaceuticals INC. | $155.50 | 2020-2021 | |
| Ardelyx, INC. | $143.02 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $128.58 | 2023 | |
| Qol Medical, LLC | $109.35 | 2019-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $107.49 | 2020-2023 | |
| Daiichi Sankyo INC. | $97.89 | 2019-2021 | |
| Madrigal Pharmaceuticals | $91.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Nevro Corp. | $80.85 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $80.84 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $68.60 | 2023-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $62.00 | 2025 | Zenpep |
| Boston Scientific Corporation | $51.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.17 | 2022 | |
| Exelixis INC. | $33.07 | 2025 | Cabometyx |
| Lilly USA, LLC | $22.26 | 2025 | Omvoh |
| Azurity Pharmaceuticals, INC. | $20.77 | 2025 | Sutab |
| Mckesson Medical-Surgical, INC. | $17.61 | 2025 | |
| Alfasigma USA, INC. | $13.12 | 2020 | |
| Digestive Care, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Premjit Chahal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.